EUVIMEDEUVIMED entdecken
Crossref

OMT-28, a synthetic analog of 17,18-epoxyeicosatetraenoic acid, mitigates lipopolysaccharide-induced lung injury in mice

Hironobu Tsubouchi, Rika Inomata, Shigehisa Yanagi, Moeka Honda, Katsuya Sakai, Anne Konkel, Janine Lossie, Wolf-Hagen Schunck, Masamitsu Nakazato, Taiga Miyazaki

European Journal of Pharmacology · 2025

DOI: 10.1016/j.ejphar.2025.178238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2025. Verfasst von Hironobu Tsubouchi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyaza…. Hauptthemen laut MEDLINE: Lipopolysaccharides, Anti-Inflammatory Agents, Respiratory Distress Syndrome, Acute Lung Injury. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute respiratory distress syndrome (ARDS) is a severe condition characterized by intense lung inflammation. Excessive oxidative stress and sustained inflammation in humans with ARDS compromise the epithelial barrier's integrity, leading to pulmonary edema, hypoxemia, and rapidly progressive respiratory failure. A cytochrome P450 metabolite of eicosapentaenoic acid (EPA), i.e., 17,18-epoxyeicosatetraenoic acid (17,18-EEQ), exhibits potent anti-inflammatory properties. We investigated the therapeutic potential of OMT-28, a metabolically stable synthetic analog of 17,18-EEQ, in a murine model of lipopolysaccharide (LPS)-induced ARDS. OMT-28 or vehicle was administered at 0.5 and 12 h after an administration of LPS. The results demonstrated that compared to the vehicle, the OMT-28 treatment significantly improved the survival rate in the post-injury period. OMT-28 also alleviated LPS-induced inflammatory cell infiltration, inhibited increased vascular permeability, reduced the levels of IL-1β, IL-6, CCL-2, and TNF-α in bronchoalveolar lavage fluid (BALF), and prevented the rise in NF-κB phosphorylation and the decrease in tight junction protein Zonula occludens-1 (ZO-1) expression. The LPS-induced lung injury led to a reduced expression of the NAD+-dependent deacetylase sirtuin-3 (Sirt3) and mitochondrial dysfunction; the OMT-28 treatment inhibited these changes. In vitro, OMT-28 treatment in LPS-stimulated human bronchial epithelial BEAS-2B cells and human alveolar epithelial A549 cells suppressed the expressions of TNF-α, IL-6, and IL-8, maintained epithelial barrier function, and preserved cell viability. SIRT3 silencing abolished the anti-inflammatory and epithelial cell integrity effects of OMT-28 in BEAS-2B cells and A549 cells. Overall, these findings indicate that OMT-28 may protect against LPS-induced lung injury by maintaining SIRT3 expression and mitochondrial function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipopolysaccharidesAnti-Inflammatory AgentsRespiratory Distress SyndromeAcute Lung InjuryLung InjuryArachidonic AcidsAnimalsMiceHumansMaleLungMice, Inbred C57BLA549 CellsDisease Models, AnimalCytokinesCapillary Permeability

Stichwörter der Autor:innen

ARDSInflammationOmega-3 epoxyeicosanoidSirtuin-3

Substanzen

LipopolysaccharidesAnti-Inflammatory Agents17,18-epoxy-5,8,11,14-eicosatetraenoic acidCytokinesArachidonic Acids

Autor:innen und Institutionen

  • Division of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Kihara 5200, Kiyotake, Miyazaki, 889-1692, Japan. Electronic addre…
  • Division of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Kihara 5200, Kiyotake, Miyazaki, 889-1692, Japan.
  • OMEICOS Therapeutics GmbH, Robert-Rössle-Straße 10, Buch, 13125, Berlin, Germany.
  • Max Delbrück Center for Molecular Medicine, Robert-Rössle-Straße 10, Buch, 13125, Berlin, Germany.
  • Forefront Research Center, Osaka University, Machikaneyamacho 1, Toyonaka, Osaka, 560-0043, Japan.

Zitieren

APA

Tsubouchi, H., Inomata, R., Yanagi, S., Honda, M., Sakai, K., Konkel, A., Lossie, J., Schunck, W. H., Nakazato, M., & Miyazaki, T. (2025). OMT-28, a synthetic analog of 17,18-epoxyeicosatetraenoic acid, mitigates lipopolysaccharide-induced lung injury in mice. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.178238

Vancouver

Tsubouchi H, Inomata R, Yanagi S, Honda M, Sakai K, Konkel A, et al. OMT-28, a synthetic analog of 17,18-epoxyeicosatetraenoic acid, mitigates lipopolysaccharide-induced lung injury in mice. European Journal of Pharmacology. 2025. doi:10.1016/j.ejphar.2025.178238

BibTeX
@article{Tsubouchi2025,
  author = {Tsubouchi, Hironobu and Inomata, Rika and Yanagi, Shigehisa and Honda, Moeka and Sakai, Katsuya and Konkel, Anne and Lossie, Janine and Schunck, Wolf-Hagen and Nakazato, Masamitsu and Miyazaki, Taiga},
  title = {OMT-28, a synthetic analog of 17,18-epoxyeicosatetraenoic acid, mitigates lipopolysaccharide-induced lung injury in mice},
  journal = {European Journal of Pharmacology},
  year = {2025},
  doi = {10.1016/j.ejphar.2025.178238}
}
Kostenlos starten →